From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2001
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 4
Total Number 4
Disease Relevance 1.32
Pain Relevance 1.97

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Fgf2) extracellular space (Fgf2) extracellular region (Fgf2)
nucleus (Fgf2) embryo development (Fgf2) cytoplasm (Fgf2)
Fgf2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Glutamate 21 100.00 Very High Very High Very High
bradykinin 9 100.00 Very High Very High Very High
metalloproteinase 110 99.80 Very High Very High Very High
Endep 3 99.54 Very High Very High Very High
COX-2 inhibitor 23 98.60 Very High Very High Very High
Nerve growth factor 31 97.24 Very High Very High Very High
antidepressant 37 95.72 Very High Very High Very High
Inflammation 67 94.32 High High
antagonist 40 92.20 High High
qutenza 4 83.48 Quite High
Disease Link Frequency Relevance Heat
Cancer 42 95.08 Very High Very High Very High
INFLAMMATION 72 94.32 High High
Sarcoma 80 91.76 High High
Ganglion Cysts 2 78.48 Quite High
Herpes Simplex Virus 238 77.60 Quite High
Primary Effusion Lymphoma 3 72.32 Quite High
Targeted Disruption 25 69.92 Quite High
Infection 105 67.72 Quite High
Stress 49 67.16 Quite High
Hyperplasia 6 63.28 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Observations such as reduced b-FGF and VEGF secretion and MMP-9 regulation reveals that COX-2 inhibitors possess the potential to be exploited in the in vivo model to better understand their benefits as an adjuvant to the currently available chemotherapy for KS.
Negative_regulation (reduced) of Localization (secretion) of b-FGF associated with sarcoma, metalloproteinase and cox-2 inhibitor
1) Confidence 0.41 Published 2010 Journal PLoS Pathogens Section Body Doc Link PMC2820536 Disease Relevance 0.98 Pain Relevance 0.33
Amitriptyline, for example, did not prevent the PMA-induced decrease of bFGF and CNTF, but it worked antagonistically for all other factors.
Negative_regulation (prevent) of Localization (decrease) of bFGF associated with endep
2) Confidence 0.20 Published 2008 Journal BMC Pharmacol Section Body Doc Link PMC2275236 Disease Relevance 0.07 Pain Relevance 0.49
3 appears to be FGF-2 produced by FS cells, because immunoneutralisation of FGF-2 abolishes the effect of TGF-?
Negative_regulation (abolishes) of Localization (immunoneutralisation) of FGF-2
3) Confidence 0.16 Published 2008 Journal Journal of Neuroendocrinology Section Body Doc Link PMC2229370 Disease Relevance 0.20 Pain Relevance 0
Incubation with growth factors generally decreased the BK-stimulated GLU release, an effect most pronounced for bFGF, which completely blocked BK-stimulated release.
Negative_regulation (decreased) of Localization (release) of bFGF associated with glutamate and bradykinin
4) Confidence 0.15 Published 2001 Journal Regul. Pept. Section Abstract Doc Link 11730978 Disease Relevance 0.08 Pain Relevance 1.14

General Comments

This test has worked.

Personal tools